Yahoo Finance LIVE – Oct 12

Motley Fool

Why AbbVie Stock Sank in September

Shares of the Illinois-based AbbVie (NYSE: ABBV) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Market Intelligence. Early on in September, the U.S. Food and Drug Administration issued a wave of new warnings for a class of drugs known as JAK inhibitors. The warning stemmed from a large safety-related study showing that patients taking Pfizer’s JAK inhibitor medication Xeljanz, an arthritis drug, were at increased risk of heart attack, stroke, cancer, blood clots, and death.

Source link:
Back to top button